According to Neurocrine Biosciences 's latest financial reports and stock price the company's current Operating Margin is 8.94%. At the end of 2021 the company had an Operating Margin of 8.95%.
Year | Operating Margin | Change |
---|---|---|
2021 | 8.95% | -12.31% |
2020 | 10.20% | 72.74% |
2019 | 5.91% | 22.01% |
2018 | 4.84% | -105.49% |
2017 | -88.19% | -90.62% |
2016 | -940.60% | 109.1% |
2015 | -449.84% | |
2013 | -1,578.97% | -16797.76% |
2012 | 9.46% | -80.52% |
2011 | 48.53% | -304.06% |
2010 | -23.78% | -98.53% |
2009 | -1,614.83% | -27.56% |
2008 | -2,229.26% | -86.84% |
2007 | -16,936.19% | 6098.17% |
2006 | -273.25% | 1425.49% |
2005 | -17.91% | -66.61% |
2004 | -53.65% | 147.89% |
2003 | -21.64% | -95.87% |
2002 | -523.89% | 487.29% |
2001 | -89.21% |
Company | Operating Margin | Operating Margin differencediff. | Country |
---|---|---|---|
![]() Pfizer PFE | 29.90% | 234.45% | ๐บ๐ธ USA |
![]() AbbVie ABBV | 23.21% | 159.62% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 23.84% | 166.67% | ๐บ๐ธ USA |
![]() Repligen
RGEN | 22.89% | 156.04% | ๐บ๐ธ USA |
![]() Athersys ATHX | -1,576.98% | -17,739.60% | ๐บ๐ธ USA |
![]() ANI Pharmaceuticals ANIP | -31.01% | -446.87% | ๐บ๐ธ USA |
![]() Palatin Technologies PTN | -2,465.05% | -27,673.27% | ๐บ๐ธ USA |
![]() Royalty Pharma RPRX | 18.68% | 108.95% | ๐ฌ๐ง UK |
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.